Source: Clinics. Conference titles: Simpósio "Avanços em Pesquisas Médicas dos Laboratórios de Investigação Médica do Hospital das Clínicas da FMUSP". Unidades: FSP, FM
Subjects: METALOPROTEINASES, PROGNÓSTICO, NEOPLASIAS PROSTÁTICAS, MATRIZ EXTRACELULAR, RESUMOS (EVENTOS)
ABNT
REIS, S T et al. Expression profiling of matrix metalloproteinase-9 and its inhibitors, TIMP-1 and reck, is associated with prognosis in prostate cancer. Clinics. São Paulo: Faculdade de Saúde Pública, Universidade de São Paulo. . Acesso em: 14 set. 2024. , 2010APA
Reis, S. T., Pontes Jr., J., Sousa-Carnavez, J. M., Silva, I. A., Antunes, A. A., Dall'Oglio, M. F., et al. (2010). Expression profiling of matrix metalloproteinase-9 and its inhibitors, TIMP-1 and reck, is associated with prognosis in prostate cancer. Clinics. São Paulo: Faculdade de Saúde Pública, Universidade de São Paulo.NLM
Reis ST, Pontes Jr. J, Sousa-Carnavez JM, Silva IA, Antunes AA, Dall'Oglio MF, Timoszczuk LMS, Nesrallah AA, Sant'Anna AC, Srougi M, Leite KRM. Expression profiling of matrix metalloproteinase-9 and its inhibitors, TIMP-1 and reck, is associated with prognosis in prostate cancer. Clinics. 2010 ; 65 S53.[citado 2024 set. 14 ]Vancouver
Reis ST, Pontes Jr. J, Sousa-Carnavez JM, Silva IA, Antunes AA, Dall'Oglio MF, Timoszczuk LMS, Nesrallah AA, Sant'Anna AC, Srougi M, Leite KRM. Expression profiling of matrix metalloproteinase-9 and its inhibitors, TIMP-1 and reck, is associated with prognosis in prostate cancer. Clinics. 2010 ; 65 S53.[citado 2024 set. 14 ]